Skip to content
value.today
Nile Therapeutics, Inc. logo

Nile Therapeutics, Inc.

Formerly SMI Products, Inc.

Total raised
$5 M
2 rounds on record
Latest round
$3 M
Jun 2011
First round on record
Jul 2009
Today
Went public
See the company page

Nile Therapeutics, Inc. is listed today as Capricor Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Nile Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2017$4 MPrivate placement after listing$2 to $10 million

Nile Therapeutics, Inc.: Private sale, May 2017

Investors in this round

4 investors had bought by the notice of May 19, 2017: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anthony Bergmann · Executive Officer
  • Deborah Ascheim · Executive Officer
  • Karen Krasney · Executive Officer
  • Leland Gershell · Executive Officer
  • Linda Marban · Executive Officer, Director
  • Rachel Smith · Executive Officer
  • David Musket · Director
  • Earl Collier · Director
  • Frank Litvack · Director
  • George Dunbar · Director
  • Joshua Kazam · Director
  • Louis Manzo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Linda Marban, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 19, 2017. Read the notice at the SEC.

equitySEC
Feb 2015$7 MPrivate placement after listing$2 to $10 million

Nile Therapeutics, Inc.: Private sale, Feb 2015

Investors in this round

8 investors had bought by the notice of Feb 19, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$364,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Hamer · Executive Officer
  • Anthony Bergmann · Executive Officer
  • Karen Krasney · Executive Officer
  • Linda Marban · Executive Officer, Director · President and Chief Executive Officer, Director
  • Rachel Smith · Executive Officer
  • David Musket · Director
  • Earl Collier, Jr. · Director
  • Frank Litvack · Director
  • George Dunbar · Director
  • Gregory Schafer · Director
  • Joshua Kazam · Director
  • Louis Grasmick · Director
  • Louis Manzo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NJ, NY
  • SC&H Capital (CRD 148291) · Sparks, MarylandSold in MD

Signed by Linda Marban, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 19, 2015. Read the notice at the SEC.

equitySEC
Jan 2015$10 MPrivate placement after listing$10 to $50 million

Nile Therapeutics, Inc.: Private sale, Jan 2015

Investors in this round

39 investors had bought by the notice of Feb 3, 2015: 39 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$126,900
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Hamer · Executive Officer
  • Anthony Bergmann · Executive Officer
  • Karen Krasney · Executive Officer
  • Linda Marban · Executive Officer, Director · President and Chief Executive Officer, Director
  • Rachel Smith · Executive Officer
  • David Musket · Director
  • Earl Collier, Jr. · Director
  • Frank Litvack · Director
  • George Dunbar · Director
  • Gregory Schafer · Director
  • Joshua Kazam · Director
  • Louis Grasmick · Director
  • Louis Manzo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in IL, NY
  • SC&H Capital (CRD 148291) · Sparks, MarylandSold in MD

Signed by Linda Marban, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 3, 2015. Read the notice at the SEC.

equitySEC
Nov 2013$26 MPrivate placement after listing$10 to $50 million

Nile Therapeutics, Inc.: Private sale, Nov 2013

Investors in this round

34 investors had bought by the notice of Dec 5, 2013: 27 accredited, 7 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Hamer · Executive Officer
  • Anthony Bergmann · Executive Officer
  • Anthony Davies · Executive Officer
  • Karen Krasney · Executive Officer
  • Linda Marban · Executive Officer, Director
  • Rachel Smith · Executive Officer
  • David Musket · Director
  • Earl Collier, Jr. · Director
  • Frank Litvack · Director
  • George Dunbar · Director
  • Gregory Schafer · Director
  • Joshua Kazam · Director
  • Louis Grasmick · Director
  • Louis Manzo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Not applicable.”
  • On the amounts: “Total shares issued pursuant to the terms of the merger agreement, multiplied by the price of the common stock ($2.50 per share after the reverse stock split) on the date of closing (11/20/2013).”
  • On a merger: “Common stock issued in connection with the merger of a wholly-owned subsidiary of Nile Therapeutics, Inc. with and into Capricor, Inc.”

Signed by Linda Marban, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 5, 2013. Read the notice at the SEC.

equitySEC
Jun 2011$3 MNo. 2$2 to $10 million

Nile Therapeutics, Inc.: Raise no. 2, Jun 2011

Investors in this round

6 investors had bought by the notice of Jun 27, 2011: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$175,000
Finders' fees
none
Paid to its own people
$307,500 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daron A Evans · Executive Officer
  • Hsiao D. Lieu · Executive Officer
  • Joshua A Kazam · Executive Officer, Director
  • Richard B. Brewer · Executive Officer, Director
  • Arie S. Belldegrun · Director
  • Frank M. Litvack · Director
  • Gregory W. Schafer · Director
  • Paul A. Mieyal · Director
  • Pedro S. Granadillo · Director
  • Peter M. Kash · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Riverbank Capital Securities, Inc. (CRD 135310) · broker-dealer Riverbank Capital Securities, Inc. (CRD 135310) · New York, New YorkSold in CA, NJ, NY
  • Ladenburg Thalmann & Co., Inc. (CRD 505) · broker-dealer Ladenburg Thalmann & Co., Inc. (CRD 505) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Plus Warrants to purchase 250,000 shares”
  • On the use of proceeds: “Represents payments of salaries to Executive Officers”

Signed by Daron Evans, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 27, 2011. Read the notice at the SEC.

equity, optionsSEC
Jul 2009$2 MNo. 1$2 to $10 million

Nile Therapeutics, Inc.: Raise no. 1, Jul 2009

Investors in this round

24 investors had bought by the notice of Jul 15, 2009: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daron Evans · Executive Officer
  • David M. Tanen · Executive Officer, Director
  • Joshua A. Kazam · Executive Officer, Director
  • Gregory W. Schafer · Director
  • Paul A. Mieyal, Ph.D. · Director
  • Pedro Granadillo · Director
  • Peter M. Kash · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Riverbank Capital Securities, Inc. (CRD 135310) · broker-dealer Riverbank Capital Securities, Inc. (CRD 135310) · New York, NySold in no state named

Remarks in the notice

  • On fees: “Riverbank was not paid a cash commission for its services, but did receive five-year warrants to purchase 218,300 shares of Company common stock at an exercise price of $1.375. Also, a non-accountable exp. allowance of $50,000 was paid.”
  • On the amounts: “The offering is being made simultaneously to U.S. and foreign investors.”

Signed by Daron Evans, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 15, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Capricor Therapeutics, Inc., its revenue in fiscal 2024 came from these business segments: Single reportable segment $22.27 million (100%).

    Annual report (SEC XBRL) · Dec 2024

  • Nile Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (May 2017).

    SEC Form D · May 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2017

Products and services#

No products or services of Nile Therapeutics, Inc. are on record.

Investors#

No investor of Nile Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 24 investors.

Largest shareholders today

Institutions holding Capricor Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Nile Therapeutics, Inc.
NameRoleNamed in
Anthony BergmannExecutive officerMay 2017
Deborah AscheimExecutive officerMay 2017
Karen KrasneyExecutive officerMay 2017
Leland GershellExecutive officerMay 2017
Linda MarbanExecutive officerMay 2017
Rachel SmithExecutive officerMay 2017
Andrew HamerExecutive officerFeb 2015
Anthony DaviesExecutive officerDec 2013
Daron A EvansExecutive officerJun 2011
Hsiao D. LieuExecutive officerJun 2011
Joshua A KazamExecutive officerJun 2011
Richard B. BrewerExecutive officerJun 2011
Daron EvansExecutive officerJul 2009
David M. TanenExecutive officerJul 2009
Joshua A. KazamExecutive officerJul 2009
David MusketDirectorMay 2017
Earl CollierDirectorMay 2017
Frank LitvackDirectorMay 2017
George DunbarDirectorMay 2017
Joshua KazamDirectorMay 2017
Linda MarbanDirectorMay 2017
Louis ManzoDirectorMay 2017
Earl Collier, Jr.DirectorFeb 2015
Gregory SchaferDirectorFeb 2015
Louis GrasmickDirectorFeb 2015
Arie S. BelldegrunDirectorJun 2011
Frank M. LitvackDirectorJun 2011
Gregory W. SchaferDirectorJun 2011
Joshua A KazamDirectorJun 2011
Paul A. MieyalDirectorJun 2011
Pedro S. GranadilloDirectorJun 2011
Peter M. KashDirectorJun 2011
Richard B. BrewerDirectorJun 2011
David M. TanenDirectorJul 2009
Joshua A. KazamDirectorJul 2009
Paul A. Mieyal, Ph.D.DirectorJul 2009
Pedro GranadilloDirectorJul 2009

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.